Headache

The evolving landscape of migraine treatment and prevention 3:42
The evolving landscape of migraine treatment and prevention
Uwe Reuter • 22 May 2020
PROMISE-1: eptinezumab in episodic migraine 2:44
PROMISE-1: eptinezumab in episodic migraine
Messoud Ashina • 29 May 2020
Understanding migraines better with AI 0:58
Understanding migraines better with AI
Dagny Holle-Lee • 20 May 2020
Fremanezumab in patients with chronic or episodic migraine 2:52
Fremanezumab in patients with chronic or episodic migraine
Uwe Reuter • 22 May 2020
CONQUER: galcanezumab in treatment-resistant migraine 9:29
CONQUER: galcanezumab in treatment-resistant migraine
Stewart Tepper • 24 May 2020
HER-MES study: erenumab versus topiramate in episodic migraine 2:30
HER-MES study: erenumab versus topiramate in episodic migraine
Uwe Reuter • 22 May 2020
Migraine: CGRP mAbs efficacy measured over time 1:30
Migraine: CGRP mAbs efficacy measured over time
Dagny Holle-Lee • 20 May 2020
The evolving migraine prevention landscape: EAN 2020 highlights 3:29
The evolving migraine prevention landscape: EAN 2020 highlights
Messoud Ashina • 29 May 2020
LIBERTY trial: erenumab in episodic migraine patients with prior preventive treatment failures 2:33
LIBERTY trial: erenumab in episodic migraine patients with prior preventive treatment failures
Uwe Reuter • 22 May 2020
PEARL study: fremanezumab for chronic or episodic migraine in the real world 3:16
PEARL study: fremanezumab for chronic or episodic migraine in the real world
Messoud Ashina • 29 May 2020
Erenumab in migraine with or without aura: cardiovascular safety 7:37
Erenumab in migraine with or without aura: cardiovascular safety
Stewart Tepper • 24 May 2020
Efficacy of galcanezumab in older patients with migraine 0:59
Efficacy of galcanezumab in older patients with migraine
Dagny Holle-Lee • 20 May 2020
The content of VJNeurology is intended for healthcare professionals